CORAL GABLES, FL / ACCESSWIRE / February 6, 2019 / The biotech stock market has always been a sector replete with innovation, and conversation surrounding companies looking into nuanced approaches to designing effective treatment options for patients suffering a wide array of diseases. According to a recent report from Deloitte regarding research and development for drug development, it costs nearly $2 billion to bring a new drug to market. Companies looking to release new drugs to the public need to assure that their products will work as a means of treatment, but will also fulfill the relevant needs of consumers looking to improve their quality of life. Companies that are able to accomplish these goals may see potential opportunities that ultimately catalyze significant investor attention. Premier Health Group (PHGRF) (PHGI), Neon Therapeutics Inc (NASDAQ: NTGN), Bionano Genomics Inc (NASDAQ: BNGO), and XBiotech Inc (NASDAQ: XBIT) represent four biotech companies working to champion new treatments for consumers in the space.
Premier Health Group (PHGRF) (PHGI) is a company focused on developing innovative approaches that combine human skill-based expertise with state-of-the-art technologies used throughout the healthcare industry to create the best-possible care solutions for their growing patient network. The Company has magnetized investors looking for opportunities in the biotech sector by strategically investing in products and services that demonstrate Premier's dedication to the industry, as well to patients simply looking for a means of feeling better.
Premier Health Group (PHGRF) (PHGI) announced towards the end of last month that, further to its new release dated January 10, 2019, the Company has acquired all outstanding securities of Cloud Practice Inc. As a result of the acquisition, Cloud Practice's Founders, including CEO Jordan Visco, and entire support team, consisting of several software developers and sales staff, will join and work alongside the Premier Health team to offer tools and resources providing for better efficiency on a day-to-day basis for both physicians and customers.
Per the official details of the agreement, Premier will pay to the Cloud Practice shareholders total consideration of up to $5 million, $2 million dollars in cash to be paid out as follows: (i) $500,000 paid in cash on signing of the binding LOI as a refundable deposit, (ii) $500,000 in cash payable on closing, (iii) $500,000 in cash payable 90 days after closing, (iv) $500,000 in cash payable within six months of the LOI subject to the satisfaction of certain milestones related to the integration of the Juno EMR, and $3 million payable in common shares of Premier at a deemed price of $0.76 per share.
Dr. Essam Hamza, CEO of Premier Health Group (PHGRF) (PHGI), commented, "we are very excited to have completed this acquisition and to have the experienced team at Cloud Practice join the team at Premier Health. With this acquisition, we now have a medical software company with national reach. Thus, enabling us to build on our patient-centric technology platform that will integrate telemedicine, online booking, and other premium services with our electronic medical records (EMR) system."
For More Information On Premier Health Group, Click Here
Neon Therapeutics Inc (NTGN) saw impressive gains in the market on Wednesday, with shares climbing 17.22% in late-afternoon trading. In early January, the Company provided a business update as well as their outlook for 2019.
Hugh O'Dowd, Neon's Chief Executive Officer, stated, "we have an exciting year ahead of us in 2019, with multiple data readouts from our personal neoantigen vaccine program, NEO-PV-01, in a variety of metastatic cancer settings using a number of rational treatment combinations. We are also continuing to investigate monotherapy opportunities and look forward to sharing our plans later this year."
For More Information On Neon Therapeutics Inc, Click Here
Bionano Genomics Inc (BNGO), a life sciences instrumentation company that develops and markets their advanced platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today announced the release of a recent publication by scientists at Wenzhou Medical University, in which the authors used Bionano's platform.
Per the publication, The authors used the Bionano Saphyr system to analyze patient samples to obtain highly accurate molecular diagnoses of facioscapulohumeral muscular dystrophy (FSHD) in a multi-generation pedigree. Scientists at these leading academic medical centers, together with commercial diagnostic laboratory Berry Genomics, used Bionano genome mapping to correctly characterize the molecular structure of the FSHD locus in the affected individuals of a five-generation pedigree.
For More Information on Bionano Genomics Inc, Click Here
XBiotech Inc (XBIT) announced towards the end of last month that the Company reported successful reports from its study using bermekimab to treat patients with moderate to severe Hidradenitis Suppurativa (HS).
Per the details of the report, Bermekimab was well-tolerated with no safety concerns. Statistically significant improvement was seen for efficacy endpoints in both anti-TNF and anti-TNF naïve groups, including the Hidradenitis Suppurativa Clinical Response Score (HiSCR); Dermatology Life Quality Index (DLQI); Physician's Global Assessment (PGA); Change in inflammatory lesion count; Disease Activity Score (DAS); and Visual Analogue Scales (VAS) for Disease Impression and Pain
For More Information On XBiotech Inc, Click Here
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.
Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 ( CASH) for & were paid "500,000" shares of restricted common shares (as of 1/2/2019). We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.
Contact Information:
SOURCE: StockPrice.com